(Q37715190)

22 August 2017

1 reference

title

Treatment with calcimimetics in kidney transplantation (English)

1 reference

22 August 2017

Enrique Morales

1

1 reference

PubMed ID

20303456

22 August 2017

Eduardo Gutierrez

series ordinal

2

1 reference

PubMed ID

20303456

22 August 2017

Amado Andres

series ordinal

3

1 reference

22 August 2017

1 April 2010

1 reference

22 August 2017

Transplantation Reviews

1 reference

22 August 2017

24

1 reference

22 August 2017

2

1 reference

22 August 2017

79-88

1 reference

Bone disease after renal transplantation

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Improvement in hypercalcemia with cinacalcet after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Bone disease after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Role of secondary hyperparathyroidism in the development of post-transplant acute tubular necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Musculoskeletal Complications After Renal Transplantation: Pathogenesis and Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Post transplant erythrocytosis in hypercalcemic renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Calcium, parathyroid hormone, and blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Parathyroid hormone and the cellular immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Hyperparathyroidism and vitamin D deficiency predispose to bone loss in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Disorders of bone and mineral metabolism after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Risk factors for fractures in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Risk factors for avascular bone necrosis after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Post-renal transplant syndrome of transient lower limb joint pain: description under a tacrolimus-based immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effect of parathyroidectomy on renal graft function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effects of parathyroidectomy on renal allograft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Calcimimetic agents: review and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Hypercalcemia after renal transplantation. Long-term follow-up data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption (plenary lecture).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Coordinated control of renal Ca(2+) transport proteins by parathyroid hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Bone involvement in idiopathic hypercalciuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet improves bone mineral density in a renal transplant recipient with persistent hyperparathyroidism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Bone disease after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

NPS R-568 halts or reverses osteitis fibrosa in uremic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

Mood disorder and chronic hypercalcemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2010.01.001

10.1016/J.TRRE.2010.01.001

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20303456